LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MicroRNA Panel Identifies Mild Brain Trauma in a Mouse Model

By LabMedica International staff writers
Posted on 23 Nov 2014
A study conducted on a mouse model found that a panel of 13 serum microRNAs (miRNAs) could be used to identify the severity of damage to the brain and the risk of developing adverse effects following mild traumatic brain injury (mTBI).

MTBI is a heterogeneous injury that may lead to the development of neurological and behavioral disorders. In the absence of specific diagnostic markers, mTBI is often unnoticed or misdiagnosed. Previous research had found a link between microRNAs—snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA—and post-traumatic stress disorder. Therefore, investigators at the Uniformed Services University of the Health Sciences (Bethesda, MD, USA) sought to identify a similar relationship between miRNAs and mTBI.

MTBI was induced in test animals by varying the weight and fall height of an impactor rod. This treatment caused four different severity grades of mTBI. Injuries were characterized as mild by neurobehavioral severity assessment one day after the injury. All of the animals recovered after day one with no significant neurobehavioral alteration by day 30 post injury.

Results from serum miRNA profiles, which were published in the November 7, 2014, online edition of the journal PLOS ONE, clearly differentiated injured from uninjured animals. Overall, the number of miRNAs that were significantly modulated in injured animals compared to controls increased with the severity of the injury. Thirteen miRNAs were found to identify mTBI regardless of its severity within the mild spectrum of injury. Bioinformatics analyses revealed that the more severe brain injuries were associated with a greater number of miRNAs involved in brain related functions.

Senior author Dr. Radha K. Maheshwari, professor of pathology at the Uniformed Services University of the Health Sciences, said, “This important finding is a step forward in identifying objective biomarkers for mTBI that may be further validated to accurately and cost-effectively identify mTBI in service members and civilians with brain injuries. Our current effort is to identify the precise role these microRNAs play in mTBI which may help in development of mTBI therapies.”

Related Links:

Uniformed Services University of the Health Sciences


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more